Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Torcetrapib SCHEMBL7169875 | 0.97 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL10041443 | 0.97 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL29403162 | 0.97 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL6277910 | 0.97 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL49081 | 0.97 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL126708 | 0.97 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL3185801 | 0.93 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3187095 | 0.93 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3187101 | 0.93 | CETP (0.92) | CETP | |
| SCHEMBL12756768 | 0.93 | CETP (0.92) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151424-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | HOFFMANN-LA ROCHE INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-9909178-B2 | Dalcetrapib for therapeutic use | HOFFMANN-LA ROCHE INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170233812-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | HOFFMANN-LA ROCHE INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160244826-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY | HOFFMANN-LA ROCHE INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233812-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | CETP, HDLBP, APOB | CETP 1/4885 |
| US-20230151424-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | CETP, HDLBP, APOB | CETP 1/4885 |
| US-20160244826-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY | CETP, HDLBP, APOB | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.